FDA Demands More Information For Amneal Parkinson’s Disease Drug

IPX203 Candidate Is ‘A Much Better Product’ Than Predecessor Rytary

Amneal says it will work closely with the FDA after seeing its application for the company’s IPX203 cardbidopa/levodopa extended-release turned down for approval by the agency.

Passport "denied" stamp
• Source: Shutterstock

Amneal Pharmaceuticals’s bid to give a lift off to its Specialty business has suffered a setback, with the US Food and Drug Administration issuing a complete response letter for the firm’s IPX203 cardbidopa/levodopa extended-release candidate, a novel new drug application indicated for the treatment of Parkinson’s disease.

The New Jersey-based firm disclosed that the FDA’s letter rejecting its NDA in its current form indicated that an adequate...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Regulation

More from Policy & Regulation

  • For Generics, A Victory Lap – And A Warning – On Drug Shortages

    Avoiding disaster at the beginning of the pandemic and offering a pro-active supply chain blueprint should position the generics industry well for an onshoring debate in Congress, but a look back at March 2020 is a reminder that even small policy shifts can have a big impact.

  • GB-Policy&Regulation-Free: Article with different widgets

    Emerging CRISPR innovations, shifting regulatory landscapes, and rising partnerships are accelerating a paradigm shift in biotech pipelines

  • Overseas API Manufacturing Identified As Key Vulnerability In US Supply Chain

    After US President Joe Biden launched a review of the country’s API supply chain, the task force has reported back with key vulnerabilities that contribute to drug shortages and supply risks during a global public health emergency. According to the report, the lack of geographic diversity and dependence on foreign nations and anti-competitive actions by foreign nations are key areas of concern.